Summit Therapeutics (SMMT) Tops Q3 EPS by 2c

Summit Therapeutics (NASDAQ: SMMT) reported Q3 EPS of (GBP0.05), GBP0.02 better than the analyst estimate of (GBP0.07).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Tradeweb Markets (TW) PT Lowered to $151 at Raymond James
• Investec Starts OnEMI Technology Solutions (KISSHT:IN) at Buy
• SpaceX (SPCX) call put ratio 1.2 calls to 1 put as share price down 5.7%